Related Experiment Video

Updated: Jun 16, 2026

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia
13:27

Osteopathic Manipulative Treatment as a Useful Adjunctive Tool for Pneumonia

Published on: May 6, 2014

Atypical pneumonia in active patients: clues, causes, and return to play

T J Melham1

  • 1Central Indiana Orthopedics and Sports Medicine Clinic, New Castle, IN, 47362, USA.

The Physician and Sportsmedicine
|January 21, 2010
PubMed

Insights

Atypical pneumonias, often seen in athletes, require cautious return-to-play guidelines due to potential severe complications. Prompt antimicrobial therapy is crucial for managing these infections.

Area of Science:

  • Infectious Diseases
  • Sports Medicine
  • Pulmonology

Background:

  • Atypical pneumonias affect young, healthy individuals, particularly those in close contact like athletes.
  • Symptoms can gradually progress and resemble upper respiratory tract infections.
  • Common agents include Mycoplasma, Chlamydia, Legionella, and certain viruses.

Purpose of the Study:

  • To highlight the risks of atypical pneumonias in athletic populations.
  • To emphasize the need for specific return-to-play guidelines.
  • To inform about appropriate antimicrobial therapies.

Main Methods:

  • Literature review of atypical pneumonia in athletes.
  • Analysis of clinical presentations and causative agents.
  • Evaluation of potential complications and recovery timelines.

Main Results:

  • Atypical pneumonias present with non-specific symptoms, delaying diagnosis.
  • Complications, though rare, can be prolonged and impact athletic careers.
  • Sudden death is a rare but possible outcome.

Conclusions:

  • Antimicrobial therapies are recommended for Mycoplasma, Chlamydia, and Legionella pneumonias.
  • Return-to-play decisions must be individualized, considering patient and sport.
  • Cautious and specific guidelines are essential to prevent adverse outcomes in athletes.

Related Concept Videos

Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...